Ryu YK, Amengual JE. Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. Lancet Haematol. 2022;9(7):e463–5.

Article  CAS  PubMed  Google Scholar 

Verma S, Goyal N, Goyal S, et al. EZH2 dysregulation and its oncogenic role in human cancers. Cancers. 2025. https://doi.org/10.3390/cancers17193111.

Article  PubMed  PubMed Central  Google Scholar 

Montani MSG, Benedetti R, Cirone M. Targeting EZH2 in cancer: mechanisms, pathways, and therapeutic potential. Molecules. 2024. https://doi.org/10.3390/molecules29245817.

Article  Google Scholar 

Xu M, Xu C, Wang R, et al. Treating human cancer by targeting EZH2. Genes Dis. 2025;12(3):101313.

Article  CAS  PubMed  Google Scholar 

Herviou L, Cavalli G, Cartron G, et al. Ezh2 in normal hematopoiesis and hematological malignancies. Oncotarget. 2016;7(3):2284–96.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. T-Cell lymphomas: version 2.2025. 2025. https://www.nccn.org/. Accessed 8 Oct 2025.

Jiangsu Hengrui Pharmaceuticals Co Ltd. First patient dosed in a pivotal study of Hengrui's novel EZH2 inhibitor (SHR2554) for the treatment of peripheral T-cell lymphoma [media release]. 13 Dec 2021. https://www.hengrui.com/.

Jiangsu Hengrui Pharmaceuticals Co Ltd. Zeprumetostat: Chinese prescribing information. 2025. https://www.hengrui.com/. Accessed 2 Oct 2025.

National Medical Products Administration. NMPA Approval notice. 2025. https://www.nmpa.gov.cn/. Accessed 2 Oct 2025.

Jiangsu Hengrui Pharmaceuticals Co Ltd. Hengrui's innovative drug 艾瑞璟®has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma [media release]. 3 Sep 2025. https://www.hengrui.com/.

Jiangsu Hengrui Pharmaceuticals Co Ltd. Hengrui Medicine's "Double Ai" combination for the first-line treatment of liver cancer has been accepted by the FDA for US marketing approval [media release]. 1 Aug 2023. https://www.hengrui.com/.

Jiangsu Hengrui Pharmaceuticals Co. L. Hengrui Medicine's innovative drug SHR2554 research results were published in The Lancet Haematology, potentially providing new options for patients with relapsed or refractory lymphoma [media release]. 27 Jul 2022. https://www.hengrui.com/.

Song Y, Liu Y, Li ZM, et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 2022;9(7):e493–503.

Article  CAS  PubMed  Google Scholar 

Li J, Hua H, Liu X, et al. Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donors. Int Immunopharmacol. 2025;162:115154.

Article  CAS  PubMed  Google Scholar 

Wu J, Hu D, Yu H, et al. Ezh2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025;16(1):522.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Wang D, Ding N, et al. The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13174249.

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Li Z, Jin Z, et al. A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 (EZH2), in relapsed or refractory (R/R) peripheral t-cell lymphoma (PTCL) [abstract no. 61 plus presentation]. Hematol Oncol. 2025;43(S3):63–4.

Article  Google Scholar 

Song Y, Jin Z, Li ZM, et al. Enhancer of Zeste Homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study. Clin Cancer Res. 2024;30(7):1248–55.

Article  CAS  PubMed  Google Scholar 

Feng K, Liu Y, Wang C, et al. Phase I study of the bifunctional anti-PD-L1/TGF-[beta]RII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors [abstract no. 2507]. J Clin Oncol. 2023;41(16 Suppl).

Zhou Y, Ding X, Zhang Y, et al. Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: a phase 2 trial [abstract no. 11549]. J Clin Oncol. 2024;42(16 Suppl).